Crossmark

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia

Crossref DOI link: https://doi.org/10.1038/s41375-024-02417-1

Published Online: 2024-09-30

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patel, Shyam A. https://orcid.org/0000-0002-8208-1902
License Information

Text and Data Mining valid from 2024-09-30

Version of Record valid from 2024-09-30
More Information

Article History

Received: 30 May 2024

Revised: 13 September 2024

Accepted: 17 September 2024

First Online: 30 September 2024

Competing interests

: SAP served on the Myelodysplastic Syndromes advisory board and the Acute Myeloid Leukemia advisory board for Bristol Myers Squibb, the Acute Leukemia advisory board for Syndax, and the Multiple Myeloma advisory board for Pfizer. SAP received travel support from AAMDSIF in 2024.

Document is current

Any future updates will be listed below